We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+18.81%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.59B
AUM Growth
+$289M
Cap. Flow
+$97.5M
Cap. Flow %
3.76%
Top 10 Hldgs %
46.26%
Holding
80
New
11
Increased
26
Reduced
24
Closed
16

Top Buys

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$75.7M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$51.8M
3
XNCR icon
Xencor
XNCR
+$48.5M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$48.4M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$39.6M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$89.8M
2
AZN icon
AstraZeneca
AZN
+$70.2M
3
CELG
Celgene Corp
CELG
+$68.1M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$61.8M
5
CTLT
CATALENT, INC.
CTLT
+$34.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.32%
2 Financials 0.74%
3 Communication Services 0.37%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$281M 10.85%
17,224,428
-1,889,436
-10% -$30.3M
ATRA icon
2
Atara Biotherapeutics
ATRA
$74.7M
$165M 6.38%
169,441
+56,801
+50% +$51.8M
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$162M 6.24%
10,738,658
+712,888
+7% +$10.8M
IMGN
4
DELISTED
Immunogen Inc
IMGN
$102M 3.94%
9,702,482
-1,204,480
-11% -$11.9M
XNCR icon
5
Xencor
XNCR
$1.39B
$96.1M 3.71%
3,204,343
+1,853,449
+137% +$48.5M
WVE icon
6
Wave Life Sciences
WVE
$1.1B
$89.7M 3.46%
2,237,607
+28,500
+1% +$1.2M
ALDR
7
DELISTED
Alder Biopharmaceuticals
ALDR
$82.6M 3.19%
6,505,766
– –
AVXS
8
DELISTED
AveXis, Inc. Common Stock
AVXS
$78.7M 3.04%
+636,900
New +$75.7M
PBYI icon
9
Puma Biotechnology
PBYI
$422M
$74.6M 2.88%
1,095,612
+182,039
+20% +$13.6M
WCG
10
DELISTED
Wellcare Health Plans, Inc.
WCG
$66.3M 2.56%
342,309
+197,960
+137% +$39.6M
ABT icon
11
Abbott
ABT
$177B
$65.7M 2.54%
1,096,100
+199,200
+22% +$12M
FATE icon
12
Fate Therapeutics
FATE
$325M
$65M 2.51%
6,655,962
+1,190,476
+22% +$11.4M
RGNX icon
13
Regenxbio
RGNX
$557M
$63.6M 2.46%
2,130,972
+705,700
+50% +$20.5M
PEN icon
14
Penumbra
PEN
$12.5B
$63.3M 2.44%
547,079
-70,200
-11% -$7.25M
CNC icon
15
Centene
CNC
$32.5B
$59.8M 2.31%
1,119,600
+36,600
+3% +$1.91M
ANAB icon
16
AnaptysBio
ANAB
$1.49B
$54.4M 2.1%
523,150
+293,300
+128% +$33.1M
SYNH
17
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$54.2M 2.09%
1,526,104
+458,786
+43% +$18M
ICUI icon
18
ICU Medical
ICUI
$3.93B
$48.8M 1.89%
193,472
+53,500
+38% +$12.6M
INSM icon
19
Insmed
INSM
$23.2B
$48.8M 1.88%
2,166,362
-82,900
-4% -$2.18M
IRTC icon
20
iRhythm Holdings
IRTC
$3.66B
$45.9M 1.77%
729,874
-84,700
-10% -$5.24M
LIVN icon
21
LivaNova
LIVN
$4.35B
$45.9M 1.77%
518,288
-97,300
-16% -$8.29M
BLUE
22
DELISTED
bluebird bio
BLUE
$45.6M 1.76%
20,620
+563
+3% +$1.43M
ALXN
23
DELISTED
Alexion Pharmaceuticals
ALXN
$45.1M 1.74%
+404,800
New +$48.4M
TFX icon
24
Teleflex
TFX
$5.93B
$45M 1.74%
176,586
+4,100
+2% +$1.08M
BOLD
25
DELISTED
Audentes Therapeutics, Inc
BOLD
$39.3M 1.52%
1,308,526
+379,200
+41% +$12.8M
1
2 3 4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q1 2018 Portfolio in Review

As of Q1 2018, Redmile Group held 80 positions worth $2.59B, up 13% from $2.3B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group deployed $97.5M of net new capital in Q1 2018, opening 11 new positions and adding to 26 existing holdings. Its largest new stake was AveXis, Inc. Common Stock: 636,900 shares worth $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $30.3M trimmed.

  • Redmile Group's largest Q1 2018 buy was AveXis, Inc. Common Stock: 636,900 shares worth $78.7M.
  • Redmile Group added most to Atara Biotherapeutics in Q1 2018, an estimated $51.8M increase.
  • Redmile Group's biggest Q1 2018 reduction was Array Biopharma Inc, cutting an estimated $30.3M.
  • Redmile Group fully exited Clovis Oncology, Inc. in Q1 2018, selling an estimated $89.8M.
  • Redmile Group's ten largest holdings make up 46% of its $2.59B portfolio in Q1 2018.
  • Redmile Group opened 11 new positions and closed 16 in Q1 2018.
  • Redmile Group's portfolio value rose 13% quarter-over-quarter to $2.59B.

Based on Redmile Group's 13F filing for Q1 2018, filed 15 May 2018.